Wolfgang Miesbach: FRONTIER4 Long-Term Results Highlight the Promise of Denecimig in Haemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”FRONTIER4 — denecimig (Mim8) long-term data presented at ISTH 2026 in Paris.
Among the clinically relevant prophylaxis updates, OC 02.4 by Jerzy Windyga reported interim safety and efficacy results from FRONTIER4, the long-term extension study of the denecimig (Mim8) programme in haemophilia A.
Denecimig is a next-generation subcutaneous FVIIIa mimetic, optimised for FIXa cofactor activity and thrombin generation.
What sets the programme apart is the dosing flexibility: once weekly, once every two weeks, or once monthly — by patient choice after week 26.
Interim analysis in adults and adolescents (≥12 years, N=365; median observation ~0.5 years):
Efficacy
- Overall estimated mean ABR 0.75, consistently low across all three schedules (QW 0.91, Q2W 0.55, QM 0.74)
- Median observed ABR was zero in every subgroup
- 71.2% with zero treated bleeds
- Low spontaneous bleeds (ABR 0.09) and near-absent target-joint bleeds (ABR 0.01, 97% zero)
- Low ABRs irrespective of FVIII inhibitor status (positive 0.15, negative 0.88)
Safety
- No thromboembolic events
- Injection-site reactions in 1.8% of injections (108/6138); the majority of AEs mild
- No clinical evidence of neutralising anti-denecimig antibodies
Monthly dosing maintained bleed protection comparable to weekly — a genuine opportunity to reduce treatment burden, with low bleed rates holding regardless of inhibitor status.
Congratulations to the investigators and, above all, to the FRONTIER4 participants.”
Stay updated with Hemostasis Today.
-
Jul 29, 2026, 17:41Seema Dawood: Difference Between CBC Smear Staining and Cell Counts Staining
-
Jul 29, 2026, 16:30Mostafa Faisal: Impact of DNMT3A and TET2 Mutations on Clotting and Bleeding in PV and ET
-
Jul 29, 2026, 16:01Gerardo Moscatelli: The Spike Protein Cascade – From Endothelial Binding to Vascular Collapse
-
Jul 29, 2026, 15:42Julie Cardoso: FDA Clears the First AI-Guided Ultrasound Software for Suspected DVT
-
Jul 29, 2026, 15:26Ahmad Alkhammash: Completing an Advanced Fellowship in Adult Thrombosis Medicine
-
Jul 29, 2026, 15:13Yara Mahmoud: The Molecular Basis in Hematology
-
Jul 29, 2026, 15:11Louisa Jorm: A New Era of Dynamic Cardiovascular Risk Assessment
-
Jul 29, 2026, 15:04Filippo Consonni: Treatment Strategies for Hematologic Immune Dysregulation in Inborn Errors of Immunity
-
Jul 29, 2026, 14:53Samer Alsaid: Warfarin Outcomes Reassessed Through COMBINE AF